Line item 1: sterility (510120GMP.BSV) units: each catalog#: 510120GMP.BSV
Ended Awarded
- Contract number
- HHSN26100012
- Awardee
-
Bioreliance Corporation UEI H3KAG9A26K77 Part of Sigma-Aldrich Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $91,832
Award facts
- Opportunity
-
- N02RC3600485 Solicitation number
- Biosafety Testing of GMP Master Cell Banks (MCB) and Retroviral Vectors for NCI Clinical Trials Award Notice · Posted Mar 7, 2013
- Contract value 100% obligated
- $91,832.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $91,832.29 firm-fixed-price delivery order to Bioreliance Corporation, a foreign-owned, for-profit organization, for sterility testing services. The contract has no set-aside designation. Bioreliance's Life Sciences Services division, doing business as Bioreliance Corp De, has extensive experience providing specialized testing services such as endotoxin, sterility, and general safety testing to support investigational new drug applications. As a subcontractor, Bioreliance has supported Colorado State University in vaccine development efforts and has provided Eb3 testing services for Regeneron Pharmaceuticals Inc. The parent company of Bioreliance is Sigma-Aldrich Corporation, a leading supplier of laboratory chemicals and related services to various industries, including biotechnology and pharmaceutical research.
Quick answers
Who was awarded contract HHSN26100012?
HHSN26100012 was awarded to Bioreliance Corporation by National Cancer Institute (National Institutes of Health) on November 22, 2013.
How much is contract HHSN26100012 worth?
The government has obligated $91,832 on HHSN26100012.
Is contract HHSN26100012 an order under another contract?
Yes. HHSN26100012 is a delivery order under HHSN261201300026I, an indefinite delivery contract.
Was contract HHSN26100012 competed?
The extent of competition for HHSN26100012 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award